✦ LIBER ✦

Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil

✍ Scribed by Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C.

Book ID: 122320867
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 81 KB
Volume: 16
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2013.08.2249

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Utility Analyses of Natalizumab Ver

Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil

✍ Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost-Effectiveness Analyses of Natalizum

Cost-Effectiveness Analyses of Natalizumab for 2nd Line Versus Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients in Brazil

✍ Nishikawa, A.M.; Paladini, L.; Liamas, A.L.; Bueno, C.C.; Clark, O.A.C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost-effectiveness of fingolimod versus

Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States

✍ Lee, Soyon; Baxter, Daniel C.; Limone, Brendan; Roberts, Matthew S.; Coleman, Cr 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 382 KB

Cost-Effectiveness Analyses of Natalizum

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

✍ Gani, Ray; Giovannoni, Gavin; Bates, David; Kemball, Belinda; Hughes, Steve; Ker 📂 Article 📅 2008 🏛 Springer International Publishing AG 🌐 English ⚖ 133 KB

Effect of prior treatment status and rea

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

✍ Khatri, B.O.; Pelletier, J.; Kappos, L.; Hartung, H.-P.; Comi, G.; Barkhof, F.; 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 600 KB